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4 times ($24,247 vs. $6,903). For the non-surgical group (N3177), however, the
total cost of all recurrences was slightly less than initial acute episode costs ($2478
vs. $2648). CONCLUSIONS: Costs associated with recurrent DV episodes are signif-
icant, with recurrences costing substantially more than initial acute episodes.
Among those with a recurrence, significant variation in costs among those with
and without surgical intervention exists.
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OBJECTIVES: Little is known about the overall burden of chronic hepatic diseases
(CHDs) for the health care third-payer, patients and their families. We performed a
Cost of Illness study named COME, to assess the societal burden (direct, indirect
and intangible costs) in patients with CHDs. The following results pertain to pa-
tients who received liver transplantation (LT). METHODS: The COME Study was a
naturalistic, multicenter, retrospective (time horizon: 6 months) work involving
1088 adult patients with CHDs. Costs were assessed from the societal perspective
and are reported as mean /patient-month (direct costs) and mean days lost from
work/study/usual activities per patient-month (loss of productivity). Patients’
Health Related Quality of Life was assessed with the EQ-5D questionnaire and is
reported as percentage of patientswith problems and asmeanSD visual analogue
scale (VAS) score. RESULTS: A total of 11.8% of the study sample had a LT. These
patients were 72.9% male, aged 19-72 (median57.5) years. Etiological agents re-
sponsible for LT were: HBV (36.2%), HCV (43.1%), HBV-HCV co-infection (3.4%),
other etiology (17.3%). Mean direct cost were 2628.8 €/patient-month. Hospitaliza-
tions contributed to 56.4% of costs, 40.2% generated from 11 patients who received
LT during the observational period. Treatment contributed to 39.5% of costs. Out-
patient contributed to 0.3% of costs. Nonmedical costs contributed to 3.7% of direct
costs. Three days/patient-month of productivity was lost by the patients and their
family caregivers. Thirty-four percent of patients reported problems in walking
about, 12.4% had problems with self-care, 42.1% had problems in doing usual ac-
tivities, 49.2% had pain or discomfort, and 40.2% had anxiety or depression. The
meanSD VAS was 69.120.5. CONCLUSIONS: High societal costs are generated
from having CHDs and in particular among patients with LT. The implementation
of efficient treatments aimed to reduce worsening of CHDs can help to improve
patients’ health and reduce societal costs.
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OBJECTIVES: The burden of Chronic Hepatic Diseases’ (CHDs) is little known. We
aimed to assess costs (direct, indirect and intangible) in patients with CHDs. The
following results pertain to patients with chronic Hepatitis C (HC).METHODS:We
conducted a naturalistic, multicenter, retrospective Cost-of-Illness study, named
COME. Costs occurring during the 6months before enrollment were assessed from
the societal perspective (i.e., NHS, patients and caregivers). Direct costs included
non medical (traveling/accommodation, formal caregiver payments) and medical
costs: conventional drug and unconventional treatment (e.g., homeopathy, herbal
medicines, vitamins, etc), hospitalization, outpatient medical visits and diagnostic
examinations. Loss of productivity was measured for patients and caregivers. Re-
sults are expressed as: €/patient-month (direct costs); days/patient-month (indi-
rect cost). Patients’ HRQoL was assessed with the EQ-5D questionnaire and is re-
ported as percentage of patients with problems and as meanSD visual analogue
scale (VAS) score. RESULTS:A total of 31.8% of the study sample (1088 patients) had
chronic HC. These patients were 54.6% male, aged 20-83 (median60.2) years.
Overall HC patients generatedmean direct costs corresponding to 233,68€/patient-
month. Treatment contributed to 71.1% of costs. Ribavirin-INF protocol was ad-
opted in 57.7% of patients. Hospitalizations contributed to 14.7% of costs and in-
volved 11.6% of the patients. Outpatient accesses contributed to 7.4% of costs and
involved 98% of the patients. Non medical costs contributed to 6.8% of direct costs
and involved 92.1% of the patients. Patients and their family caregivers lost on
average 0.7 days/patient-month of productivity. Twenty percent of patients re-
ported problems in walking about, 12.5% had problems with self-care, 25.4% had
problems in doing usual activities, 36.3% had pain/discomfort, and 44.7% had anx-
iety/depression. The meanSD VAS was 68.820.3. CONCLUSIONS: Chronic HC
generates high costs to the health care system. The use of efficient treatments is
necessary to reduce worsening of patients’ health, direct and indirect costs.
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OBJECTIVES: The burden of Chronic Hepatic Diseases (CHDs) is little known. We
aimed to assess social burden (direct, indirect and intangible cost) in patients with
CHDs. The following results pertain to patients with chronic Hepatitis B (HB).
METHODS: COME is a naturalistic, multicenter, retrospective cost of illness study.
Costs occurring during the 6 months before enrollment were assessed from the
societal perspective. Direct costs included nonmedical (traveling/accommodation,
caregiver payments) and medical costs: conventional (drug) and unconventional
treatment (e.g., homeopathy, vitamins, etc), hospitalization, outpatient medical
visits and diagnostic examinations. Loss of productivity wasmeasured for patients
and caregivers. Results are expressed as: €/patient-month (direct costs); days/pa-
tient-month (indirect costs). Patients’ HRQoL was assessed with the EQ-5D ques-
tionnaire and is reported as percentage of patientswith problems and asmeanSD
VAS score. RESULTS: Among 1088 adult patients enrolled, 221 had chronic HB
(20.3%). These patients were 69.7% male, aged 19-81(median56.1) years. Overall
HB patients generated mean direct costs corresponding to 308.1€/patient-month.
Treatment contributed to 76.9% of costs, involving 53.4% of the patients. In partic-
ular, 46.2% of patients were treated with antiviral drugs for systemic use (lamivu-
dine, ribavirin, etc). Hospitalizations contributed to 12.9% of costs and involved
9.0% of the patients. Outpatient accesses contributed to 5.4% of costs and involved
99.1% of the patients. Non medical costs contributed to 4.8% of direct costs and
involved 90.8% of the patients. Patients and their family caregivers lost on average
0.4 days/patient-month of productivity. As regardsHRQoL, patients reporting prob-
lems were: 24.4% of patients in walking about, 12.0% in self-care, 30.5% in usual
activities, 36.1% in pain/discomfort and 45.6% in anxiety/depression domain. The
meanSD VAS was 71.2520.72. CONCLUSIONS: Chronic HB generates high costs
to the healthcare system. The use of efficient treatments is necessary to reduce
worsening of patients’ health, direct and indirect costs.
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OBJECTIVES:We assessed changes in utilization of common chronic-use medica-
tions and generalized all-causemedical services and costs pre- to post-diagnosis in
a real-world diverticulitis (DV) population.METHODS: Insurance claims from 40
US health plans representing 50 million lives were retrospectively analyzed. In-
clusion criteria were: primary diagnosis of colonic DV (ICD-9 562.11, 562.13) be-
tween January 1, 2005 and December 31, 2008; antibiotic within 3 days post-diag-
nosis; 12 months pre- and post-diagnosis enrollment. Use of non-GI-related
medications, as well as overall all-cause utilization and costs (2009 US$), were
descriptively evaluated pre- to post-diagnosis. All-cause costs were also evaluated
for non-DV controls matched 2:1 on age, gender, and plan enrollment, with index
date assigned as diagnosis date of each respective DV match. RESULTS: A total of
25,172 patients met all inclusion criteria (51.2% male, mean age 53 years). The top
5 most prevalent chronic-use medications during pre-index were antihyperlipi-
demics (30.0% of patients), antihypertensives (27.5%), antidepressants (20.9%), der-
matologicals (20.0%) and beta blockers (15.7%). Post-index use of thesemedications
increased by 8.9%, 8.2%, 7.3%, 9.1%, and 11.7%, respectively (all P0.010). Mean
all-cause hospital days and costs per patient increased significantly pre- to post-
index (0.9 vs. 2.3 days, $3223 vs. $6341; all P0.010). Other significant (P0.010)
increases pre- to post-index were seen for ER visits (0.7 vs. 1.2; $432 vs. $1012),
prescriptions (22 vs. 27 fills, $1910 vs. $2081), office visits (10 vs. 12, $1747 vs. $2251),
and other outpatient/specialty consultations (3 vs. 5, $2676 vs. $4288) (all P0.010).
Total all-cause costs increased by 60%post-diagnosis ($10,419 vs. $16,672; P0.010).
Minimal change occurred for controls ($6299 vs. $6493; P0.010). CONCLUSIONS:
Patients with DV have higher use of common chronic-use prescriptions after diag-
nosis, as well as significantly higher use and costs of general all-cause medical
services. Payers should be aware of increased costs for not only disease-related
services, but also other general health care.
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OBJECTIVES: Clostridium difficile-associated disease (CDAD) is a nosocomial gas-
trointestinal infection that has been associated with increases in health care costs.
Fidaxomixin was recently approved for CDAD but is costly compared to conven-
tional agents. We evaluated the cost-effectiveness of fidaxomicin, metronidazole,
and vancomycin in the treatment of CDAD.METHODS: A decision analysis model
was created to estimate the cost-effectiveness of fidaxomicin, metronidazole, and
vancomycin in clinical cure from the US health care payer perspective. Parameters
for the model were determined from the published literature and indirect treat-
ment comparison was performed using Bayesian methods to obtain the probabil-
ities for responder and recurrence rates. Medication costs were determined from
the AWP and resource costs were determined fromCPT and HCPCS codes. All costs
were adjusted for 2011 US dollars. Probabilities of responder and recurrence, costs,
and resource utilization were fitted with a beta, gamma, and triangle distribution,
respectively. Probabilistic sensitivity analysis with 10,000 trial simulations was
performed to test the robustness of the model. Probabilities of cost-effectiveness
for different treatment strategieswere plotted on a cost-effectiveness acceptability
frontier (CEAF). RESULTS: The total direct costs for fidaxomicin, metronidazole,
and vancomycin were $14,219.98, $13,927.53, and $13,554.08, respectively. The
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